For the year ending 2025-12-31, PSTV had $8,682K increase in cash & cash equivalents over the period. -$20,842K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -22,386 |
| Depreciation and amortization | 445 |
| Accretion of discount on short-term investments | 9 |
| Noncash financing expenses | 3,061 |
| Change in fair value of derivative instruments | 2,631 |
| Stock compensation expense | 1,540 |
| Gain on sale of assets | 16 |
| Grant receivable | -249 |
| Other assets | 763 |
| Accounts payable and accrued expenses | -5,620 |
| Other liabilities | 159 |
| Change in operating lease liabilities | -66 |
| Net cash used in operating activities | -20,775 |
| Purchases of property and equipment | 67 |
| Proceeds from sale of property and equipment | 30 |
| Purchases of short-term investments | 9,353 |
| Proceeds from redemption of short-term investments | 3,768 |
| Proceeds from sales of short-term investments | 4,768 |
| Net cash used in investing activities | -854 |
| Proceeds from credit facility | 750 |
| Repayment of credit facility | 3,292 |
| Payment of financing costs | 2,250 |
| Proceeds from issuance of notes payable and warrants | 3,738 |
| Repayment of notes payable | 3,703 |
| Proceeds from sale of common stock, pre-funded warrants, and warrants | 15,926 |
| Proceeds from sale of common stock under lincoln park purchase agreement | 22,615 |
| Payment to investors pursuant to letter agreement | 3,242 |
| Offering costs for sale of common stock | 231 |
| Net cash provided by financing activities | 30,311 |
| Net increase (decrease) in cash and cash equivalents | 8,682 |
| Cash, cash equivalents, and restricted cash at beginning of period | 76 |
| Cash, cash equivalents, and restricted cash at end of period | 8,758 |
PLUS THERAPEUTICS, INC. (PSTV)
PLUS THERAPEUTICS, INC. (PSTV)